NRx Pharmaceuticals and Nephron Pharmaceuticals announced the signing of a development and manufacturing agreement to manufacture a presentation of ketamine suitable for treating suicidal depression. Recent CDC data suggest that more than 3M Americans have active thoughts of suicide and more than 50,000 die from suicide each year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NRXP:
- NRx Pharmaceuticals receives ‘study may proceed’ letter from FDA for NRX-101
- NRx Pharmaceuticals announces acceleration in development of NRX-100
- NRx Pharmaceuticals receives FDA clearance to proceed on NRX-101 NDA
- NRx Pharmaceuticals sees potential NDA filing for NRX-100 in 2024
- NRx Pharmaceuticals signs data sharing agreement for ketamine treatment